摘要
目的 观察立普妥联合心脉通对冠心病合并高血脂患者的临床效果。方法 选取北海市人民医院2017年1月至2018年1月收治的冠心病合并高血脂患者50例作为研究对象,随机分成对照组和观察组,每组25例。对照组患者给予立普妥进行常规治疗,观察组患者给予立普妥进行治疗的基础上再给予心脉通进行治疗。对比两组治疗效果。结果 两组患者经过治疗后,观察组患者的总胆固醇和低密度脂蛋白等血脂指标均低于对照组(P <0.05);两组患者临床治疗效果对比中,观察组患者的治疗总有效率为96.00%,显著高于对照组(64.00%,P <0.05)。结论 冠心病合并高血脂患者给予立普妥联合心脉通进行临床治疗,能够有效的降低患者的血脂指标,稳定总胆固醇和低密度脂蛋白,具有较高的临床用药安全性。
Objective To analyze the clinical effect of Lipitor combined with Xinmaitong in patients with coronary heart disease and hyperlipidemia.Methods From January 2017 to January 2018,50 patients with coronary heart disease complicated with hyperlipidemia were randomly divided into control group and observation group,with 25 patients in each group.The patients in the control group were given Lipitor,the patients in the observation group were treated with Lipitor and Xinmaitong.Treatment effect of the two groups were compared.Results After treatment,the total cholesterol and low density lipoprotein and other blood lipid indexes in the observation group were lower than those in the control group(P<0.05).In the comparison of clinical treatment effect between the two groups,the total effective rate of treatment in the observation group was 96.00%,significantly higher than that in the control group(64.00%,P<0.05).Conclusion The combination of Lipitor and Xinmaitong in patients with coronary heart disease and hyperlipidemia can effectively reduce the blood lipid index,stabilize total cholesterol and low density lipoprotein,and have high clinical safety.
作者
袁明慧
YUAN Minghui(Department of Pharmacy,Beihai People's Hospital,Beihai,Guangxi 536000,China)
出处
《大医生》
2019年第3期93-94,共2页
Doctor
